CO2021004529A2 - Proceso de elaboración de alfa-cetoglutarato de calcio referencia cruzada con solicitudes relacionadas - Google Patents

Proceso de elaboración de alfa-cetoglutarato de calcio referencia cruzada con solicitudes relacionadas

Info

Publication number
CO2021004529A2
CO2021004529A2 CONC2021/0004529A CO2021004529A CO2021004529A2 CO 2021004529 A2 CO2021004529 A2 CO 2021004529A2 CO 2021004529 A CO2021004529 A CO 2021004529A CO 2021004529 A2 CO2021004529 A2 CO 2021004529A2
Authority
CO
Colombia
Prior art keywords
ketoglutarate
manufacturing process
related applications
cross reference
process cross
Prior art date
Application number
CONC2021/0004529A
Other languages
English (en)
Inventor
David Eugene Pereira
Keshav Deo
Original Assignee
Ponce De Leon Health Designated Activity Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ponce De Leon Health Designated Activity Company filed Critical Ponce De Leon Health Designated Activity Company
Publication of CO2021004529A2 publication Critical patent/CO2021004529A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/418—Preparation of metal complexes containing carboxylic acid moieties
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/347—Saturated compounds containing more than one carboxyl group containing keto groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se describen métodos y procesos para preparar sales de calcio de alfa-cetoglutarato.
CONC2021/0004529A 2018-09-25 2021-04-11 Proceso de elaboración de alfa-cetoglutarato de calcio referencia cruzada con solicitudes relacionadas CO2021004529A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862736320P 2018-09-25 2018-09-25
PCT/US2019/052498 WO2020068705A1 (en) 2018-09-25 2019-09-23 Process of making calcium alpha-ketoglutarate

Publications (1)

Publication Number Publication Date
CO2021004529A2 true CO2021004529A2 (es) 2021-04-30

Family

ID=69952136

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0004529A CO2021004529A2 (es) 2018-09-25 2021-04-11 Proceso de elaboración de alfa-cetoglutarato de calcio referencia cruzada con solicitudes relacionadas

Country Status (17)

Country Link
US (1) US11802103B2 (es)
EP (1) EP3856166A4 (es)
JP (1) JP2022502489A (es)
KR (1) KR20210065120A (es)
CN (1) CN112955139A (es)
AU (1) AU2019350699B2 (es)
BR (1) BR112021005668A2 (es)
CA (1) CA3112205A1 (es)
CL (1) CL2021000728A1 (es)
CO (1) CO2021004529A2 (es)
IL (1) IL281761A (es)
MX (1) MX2021003482A (es)
PE (1) PE20211816A1 (es)
PH (1) PH12021550403A1 (es)
SG (1) SG11202102204PA (es)
TW (1) TW202024013A (es)
WO (1) WO2020068705A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022502489A (ja) 2018-09-25 2022-01-11 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
CN112941116B (zh) * 2021-01-04 2022-12-02 上海朴颐化学科技有限公司 一种酶法制备α-酮戊二酸钙的方法
CN114105761A (zh) * 2021-11-19 2022-03-01 广东派特埃尔生物科技有限公司 一种α-酮戊二酸钠盐的合成工艺

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776926A (en) 1955-08-04 1957-01-08 Eugene S Sharpe Preparation of alpha-ketoglutaric acid by serratia marcescens
US2917528A (en) 1956-08-24 1959-12-15 Victor Chemical Works Alkanolaminealkanephosphonic acids and salts thereof
US2841616A (en) * 1956-10-30 1958-07-01 Campbell Soup Co Process for the recovery of alpha-ketoglutaric acid
US3875304A (en) 1970-04-24 1975-04-01 Schlitz Brewing Co J Livestock feed composition and method of preparing the same
US4045585A (en) 1976-05-19 1977-08-30 Decel Corporation Flavored animal food compositions
DE3151196A1 (de) * 1981-12-23 1983-06-30 Kurt Heinz Prof. Dr. 7800 Freiburg Bauer Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen
US6451341B1 (en) 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
US5646187A (en) 1992-05-20 1997-07-08 Ab Erik Vinnars Use of alpha-ketoglutarate
US6306430B1 (en) 1998-04-16 2001-10-23 The Iams Company Process for decreasing adiposity using vitamin a as a dietary supplement
US6905707B2 (en) 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
CO5140079A1 (es) 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
WO2002049552A2 (en) 2000-12-20 2002-06-27 Alcon, Inc. Solution for removing cataracts via liquefracture
EP1744770A2 (en) * 2004-05-06 2007-01-24 Osteologix A/S High yield and rapid syntheses methods for producing metallo-organic salts
PL368572A1 (en) * 2004-06-17 2005-12-27 Sgp & Sons Ab Pharmaceutical compound for prevention and therapy of increased level of cholesterol, ldl and triglycerides as well as application of the pharmaceutical compound as an agent acting against atherosclerosis and used in circulatory system affections
AU2005271053A1 (en) 2004-08-09 2006-02-16 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
CA2911468C (en) 2004-12-17 2018-04-24 Alan B. Cash Oxaloacetate, oxaloacetic acid, and oxaloacetate salts for delaying the onset of neurodegenerative diseases
US20060234250A1 (en) 2005-04-15 2006-10-19 Powers Ralph W Iii Methods of screening and compositions for life span modulators
WO2007001883A2 (en) 2005-06-20 2007-01-04 Accera, Inc. Method to reduce oxidative damage and improve mitochondrial efficiency
CA2628265A1 (en) 2005-11-08 2007-05-18 Multi Formulations Ltd. The use of compositions comprising ketoacids and amino acids for increasing muscle mass and muscle performance
US8367121B2 (en) 2005-11-23 2013-02-05 Florida A & M University Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease
PL379512A1 (pl) 2006-04-21 2007-10-29 Sgp & Sons Ab Nowe metody i ich zastosowanie
PL226695B1 (pl) 2006-07-03 2017-08-31 Danuta Kruszewska Środek do zastosowania w zapobieganiu i/lub hamowaniu kolonizacji Helicobacter pylori, zastosowanie soli kwasu alfa‑ketoglutarowego z metalami alkalicznymi i ziem alkalicznych do wytwarzania środka leczniczego oraz dodatku do żywności do zapobiegania i/lub hamowania kolonizacji Helicobacter pylori
JP2010522190A (ja) 2007-03-19 2010-07-01 メタプロテオミクス， エルエルシー 骨及び関節の健康を助成するための方法と組成物
CA2691746C (en) 2007-07-02 2016-02-02 Entress Ab Use of alpha-ketoglutarate in the treatment of hypertension
EP2033623A1 (en) 2007-09-07 2009-03-11 Cutech S.R.L. Compositions comprising ornithine ketoglutarate (OKG)
CN101759553A (zh) 2008-11-21 2010-06-30 扬子江药业集团北京海燕药业有限公司 α-酮酸钙的制备方法
DE102009016119A1 (de) 2009-04-03 2010-10-14 Evonik Degussa Gmbh Nahrungsergänzungsmittel enthaltend alpha-Ketosäuren zur Unterstützung der Diabetestherapie
ES2685947T3 (es) 2009-04-10 2018-10-15 Haiyan Qi Agentes antienvejecimiento
EA201101519A1 (ru) 2009-05-11 2012-10-30 БЕРГ БАЙОСИСТЕМЗ, ЭлЭлСи Способы диагностики метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
JP2012527894A (ja) 2009-05-28 2012-11-12 ザ・アイムス・カンパニー 被覆キブル形態のペットフード
CN102548560B (zh) 2009-06-12 2016-01-20 基因雷克斯制药有限公司 用于预防和治疗冠心病的组合物和方法
JP6159084B2 (ja) 2009-06-30 2017-07-05 デルマン バイオメディシン カンパニー リミテッド 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
US9283257B2 (en) 2009-11-12 2016-03-15 Nox Technologies, Inc. Compositions comprising solanum tuberosum for lowering cytosolic NADH level to mimic calorie restriction
WO2012114204A2 (en) 2011-02-15 2012-08-30 Ecole Polytechnique Federale De Lausanne (Epfl) Epfl-Tto Methods of treating mitochondrial dysfunction
RU2013151085A (ru) 2011-04-18 2015-05-27 Нестек С.А. ПИТАТЕЛЬНЫЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ α-ГИДРОКСИИЗОКАПРОНОВУЮ КИСЛОТУ(α-HICA), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2012174537A2 (en) 2011-06-16 2012-12-20 President And Fellows Of Harvard College Small molecule screening for mouse satellite cell proliferation
WO2013152120A2 (en) 2012-04-03 2013-10-10 Whitehead Institute For Biomedical Research Compositions and methods for promoting intestinal stem cell function
ITBO20120226A1 (it) 2012-04-24 2013-10-25 Alfa Wassermann Spa Composizioni comprendenti ornitina alfa-chetoglutarato, processi per il loro ottenimento e il loro uso.
ES2681343T3 (es) 2012-09-19 2018-09-12 Grespo Ab Composiciones para la mejora de la función cerebral
CN102976927A (zh) * 2012-12-26 2013-03-20 天津天成制药有限公司 α-酮戊二酸钙的制备方法
CA2896646A1 (en) 2012-12-27 2014-07-03 Hayashibara Co., Ltd. Skin-exterior anti-ageing composition and production method therefor
WO2014116985A1 (en) 2013-01-25 2014-07-31 Winning The Fight Inc. Composition for treatment of neurodegenerative disease
US9511057B2 (en) 2013-03-15 2016-12-06 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating denervation-induced muscle atrophy
BR112015024186B1 (pt) 2013-03-19 2023-05-09 University Of South Florida Composições e métodos para produção de cetose de elevação e manutenção
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
EP3104852A4 (en) 2014-02-12 2017-12-13 The Regents Of The University Of California Compositions and methods for treating aging and age-related diseases and symptoms
WO2015171723A1 (en) 2014-05-06 2015-11-12 Research Development Foundation Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy
WO2016003854A1 (en) 2014-06-30 2016-01-07 The Regents Of The University Of California Ketobutyrate compounds and compositions for treating age-related symptoms and diseases
US10301303B2 (en) 2014-07-29 2019-05-28 Shenzhen Hightide Biopharmaceutical, Ltd. Berberine salts, ursodeoxycholic salts and combinations, methods of preparation and application thereof
WO2016019224A1 (en) 2014-07-31 2016-02-04 Indiana University Research And Technology Corporation Antithetical regulation of endothelial ace and ace2 by brg1-foxm1 complex underlies pathological cardiac hypertrophy
AU2016245590A1 (en) 2015-04-06 2017-10-19 Shenzhen Hightide Biopharmaceutical, Ltd. Conjugate compounds of ursodeoxycholic, berberine or L-carnitine, and compositions and methods thereof
US11426398B2 (en) 2015-06-10 2022-08-30 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
US20180193458A1 (en) 2015-07-08 2018-07-12 Unity Biotechnology, Inc. Compositions and methods for treating senescence-associated diseases and disorders
CN109803647A (zh) 2016-09-30 2019-05-24 加州大学董事会 α-丁酮酸、α-酮戊二酸和2-羟基丁酸用于刺激毛发生长
PL231635B1 (pl) 2017-01-03 2019-03-29 Politechnika Poznanska Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych
MX2017004010A (es) 2017-03-27 2018-02-09 Antonio Hernandez Miramontes Jorge Mezcla de oxalacetato, alfacetoglutarato, ácido tartánico y sales de lactato de calcio y sodio, para tratar pacientes con insuficiencia renal crónica.
EP3615029A4 (en) 2017-04-25 2021-04-21 Buck Institute for Research on Aging FORMULATIONS TO EXTEND LIFE AND HEALTH LIFETIME
WO2019038655A1 (en) 2017-08-21 2019-02-28 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES
JP2022502489A (ja) 2018-09-25 2022-01-11 ポンス デ レオン ヘルス デジグネイテッド アクティビティ カンパニー αケトグルタル酸カルシウムを製造するためのプロセス
JP2022504771A (ja) 2018-10-24 2022-01-13 ポンセ デ レオン ヘルス デシグネイテッド アクティビティ カンパニー 健康寿命延長を目的とするニコチンアミドリボシド組成物
EP3980001A4 (en) 2019-06-10 2023-06-21 Ponce de Leon Health Designated Activity Company COMPOSITIONS OF ALPHA-KETOGLUTARATE DELAYED RELEASE
WO2020252005A1 (en) 2019-06-10 2020-12-17 Buck Institute For Research On Aging Methods and compositions for altering senescence associated secretory phenotype
US20230255912A1 (en) 2020-07-02 2023-08-17 Ponce De Leon Health Designated Activity Company Compositions and methods for treating crp-mediated diseases

Also Published As

Publication number Publication date
KR20210065120A (ko) 2021-06-03
AU2019350699B2 (en) 2024-05-23
TW202024013A (zh) 2020-07-01
PH12021550403A1 (en) 2021-10-04
US20210371368A1 (en) 2021-12-02
EP3856166A1 (en) 2021-08-04
AU2019350699A1 (en) 2021-04-08
US11802103B2 (en) 2023-10-31
IL281761A (en) 2021-05-31
WO2020068705A1 (en) 2020-04-02
CL2021000728A1 (es) 2021-10-22
SG11202102204PA (en) 2021-04-29
CA3112205A1 (en) 2020-04-02
PE20211816A1 (es) 2021-09-14
CN112955139A (zh) 2021-06-11
BR112021005668A2 (pt) 2021-06-22
MX2021003482A (es) 2021-06-18
JP2022502489A (ja) 2022-01-11
EP3856166A4 (en) 2022-06-22

Similar Documents

Publication Publication Date Title
CO2021004529A2 (es) Proceso de elaboración de alfa-cetoglutarato de calcio referencia cruzada con solicitudes relacionadas
MX2018010427A (es) Formas solidas de un inhibidor de tienopirimidindiona acetil coa carboxilasa y metodos para su produccion.
CL2019002824A1 (es) Anticuerpos anti-lag3.
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
CL2019002793A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma.
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
CL2020000946A1 (es) Métodos y composiciones para la producción de trifosfato de nucleosido y ácido ribonucleico
BR112017024676A2 (pt) ?métodos para produzir biohidrocarbonetos e mistura de biohidrocarbonetos?
CL2020000190A1 (es) Inhibidores de ror-gamma.
EA201891446A1 (ru) Молекулы полиспецифичных антител, имеющие специфичность к tnf-альфа, il-17a и il-17f
BR112016029730A2 (pt) microrganismo do género corynebacterium que tem a aptidão de produzir l-arginina e um método para a produção de l-arginina utilizando o mesmo".
CL2020000217A1 (es) Inhibidores de ror gamma.
BR112016025999A2 (pt) micro-organismo tendo produtividade de l-lisina aperfeiçoada e método para produção de l-lisina usando o mesmo
BR112022001016A2 (pt) Métodos de produção de aflibercepte
BR112019020338A8 (pt) Composição para produção de tagatose, e, método de produção de tagatose
BR112018003756A2 (pt) microorganismo corynebacterium sp. capaz de produzir l-lisina e método para produzir l-lisina usando o mesmo
BR112017019176A2 (pt) processos para a preparação de fluorocetolídeos
EA202191840A1 (ru) Способы получения устекинумаба
BR112018004247A2 (pt) método para produção de ésteres de cianidrina contendo fósforo.
BR112017025873A2 (pt) método para revestir a cabeça de um pirulito com um material de revestimento
CL2021001363A1 (es) Métodos de tratamiento de enfermedades con inhibidores de magl.
BR112019006310A2 (pt) método para fabricar digliceróxido de cálcio
CL2023001137A1 (es) Procedimiento para la purificación de pleuromutilinas
BR112017023877A2 (pt) método de produção de um composto à base de mercúrio, o composto à base de mercúrio, os métodos para utilização do composto à base de mercúrio e as utilizações do composto à base de mercúrio
CO2020006542A2 (es) Profármacos de creatina, composiciones y métodos de uso de estos